MicroRNAs (miRNAs) are small non-coding ribonucleic acids (RNAs) which play key roles in post-transcriptional gene regulation. Direct identification of mature miRNAs is infeasible due to their short lengths, and researchers instead aim at identifying precursor miRNAs (pre-miRNAs). Many of the known pre-miRNAs have distinctive stem-loop secondary structure, and structure-based filtering is usually the first step to predict the possibility of a given sequence being a pre-miRNA. To identify new pre-miRNAs that often have non-canonical structure, however, we need to consider additional features other than structure. To obtain such additional characteristics, existing computational methods rely on manual feature extraction, which inevitably limits the efficiency, robustness, and generalization of computational identification. To address the limitations of existing approaches, we propose a pre-miRNA identification method that incorporates (1) a deep recurrent neural network (RNN) for automated feature learning and classification, (2) multimodal architecture for seamless integration of prior knowledge (secondary structure), (3) an attention mechanism for improving long-term dependence modeling, and (4) an RNN-based class activation mapping for highlighting the learned representations that can contrast pre-miRNAs and non-pre-miRNAs. In our experiments with recent benchmarks, the proposed approach outperformed the compared state-of-the-art alternatives in terms of various performance metrics.

MiRNAs, due to their role in gene regulation, have paved a new pathway for pharmacology, focusing on drug development that targets miRNAs. However, traditional wet lab experiments are limited by efficiency and cost constraints, making it difficult to extensively explore potential associations between developed drugs and target miRNAs. Therefore, we have designed a novel machine learning model based on a multi-layer transformer-based graph neural network, DMAGT, specifically for predicting associations between drugs and miRNAs. This model transforms drug-miRNA associations into graphs, employs Word2Vec for embedding features of drug molecular structures and miRNA base structures, and leverages a graph transformer model to learn from embedded features and relational structures, ultimately predicting associations between drugs and miRNAs. To evaluate DMAGT, we tested its performance on three datasets composed of drug-miRNA associations: ncDR, RNAInter, and SM2miR, achieving up to AUC of $95.24\pm0.05$. DMAGT demonstrated superior performance in comparative experiments tackling similar challenges. To validate its practical efficacy, we specifically focused on two drugs, namely 5-Fluorouracil and Oxaliplatin. Of the 20 potential drug-miRNA associations identified as the most likely, 14 were successfully validated. The above experiments demonstrate that DMAGT has an excellent performance and stability in predicting drug-miRNA associations, providing a new shortcut for miRNA drug development.

MicroRNAs (miRNAs) are small non-coding ribonucleic acids (RNAs) which play key roles in post-transcriptional gene regulation. Direct identification of mature miRNAs is infeasible due to their short lengths, and researchers instead aim at identifying precursor miRNAs (pre-miRNAs). Many of the known pre-miRNAs have distinctive stem-loop secondary structure, and structure-based filtering is usually the first step to predict the possibility of a given sequence being a pre-miRNA. To identify new pre-miRNAs that often have non-canonical structure, however, we need to consider additional features other than structure. To obtain such additional characteristics, existing computational methods rely on manual feature extraction, which inevitably limits the efficiency, robustness, and generalization of computational identification. To address the limitations of existing approaches, we propose a pre-miRNA identification method that incorporates (1) a deep recurrent neural network (RNN) for automated feature learning and classification, (2) multimodal architecture for seamless integration of prior knowledge (secondary structure), (3) an attention mechanism for improving long-term dependence modeling, and (4) an RNN-based class activation mapping for highlighting the learned representations that can contrast pre-miRNAs and non-pre-miRNAs. In our experiments with recent benchmarks, the proposed approach outperformed the compared state-of-the-art alternatives in terms of various performance metrics.

Integrating multi-omics data, such as DNA methylation, mRNA expression, and microRNA (miRNA) expression, offers a comprehensive view of the biological mechanisms underlying disease. However, the high dimensionality and complex interactions among omics layers present major challenges for predictive modeling. We propose Multi-Omics integration with Tree-generated Graph Neural Network (MOTGNN), a novel and interpretable framework for binary disease classification. MOTGNN employs eXtreme Gradient Boosting (XGBoost) to perform omics-specific supervised graph construction, followed by modality-specific Graph Neural Networks (GNNs) for hierarchical representation learning, and a deep feedforward network for cross-omics integration. On three real-world disease datasets, MOTGNN outperforms state-of-the-art baselines by 5-10% in accuracy, ROC-AUC, and F1-score, and remains robust to severe class imbalance (e.g., 87.2% vs. 33.4% F1 on imbalanced data). The model maintains computational efficiency through sparse graphs (2.1-2.8 edges per node) and provides built-in interpretability, revealing both top-ranked biomarkers and the relative contributions of each omics modality. These results highlight MOTGNN's potential to improve both predictive accuracy and interpretability in multi-omics disease modeling.

Given the increasing complexity of omics datasets, a key challenge is not only improving classification performance but also enhancing the transparency and reliability of model decisions. Effective model performance and feature selection are fundamental for explainability and reliability. In many cases, high dimensional omics datasets suffer from limited number of samples due to clinical constraints, patient conditions, phenotypes rarity and others conditions. Current omics based classification models often suffer from narrow interpretability, making it difficult to discern meaningful insights where trust and reproducibility are critical. This study presents a machine learning based classification framework that integrates feature selection with data augmentation techniques to achieve high standard classification accuracy while ensuring better interpretability. Using the publicly available dataset (E MTAB 8026), we explore a bootstrap analysis in six binary classification scenarios to evaluate the proposed model's behaviour. We show that the proposed pipeline yields cross validated perfomance on small dataset that is conserved when the trained classifier is applied to a larger test set. Our findings emphasize the fundamental balance between accuracy and feature selection, highlighting the positive effect of introducing synthetic data for better generalization, even in scenarios with very limited samples availability.

Feature selection can greatly improve performance and interpretability in machine learning problems. However, existing nonparametric feature selection methods either lack theoretical error control or fail to accurately control errors in practice. Many methods are also slow, especially in high dimensions. In this paper, we introduce a general feature selection method that applies integrated path stability selection to thresholding to control false positives and the false discovery rate. The method also estimates q-values, which are better suited to high-dimensional data than p-values. We focus on two special cases of the general method based on gradient boosting (IPSSGB) and random forests (IPSSRF). Extensive simulations with RNA sequencing data show that IPSSGB and IPSSRF have better error control, detect more true positives, and are faster than existing methods. We also use both methods to detect microRNAs and genes related to ovarian cancer, finding that they make better predictions with fewer features than other methods.

Determining interactions between entities and the overall organization and clustering of nodes in networks is a major challenge when analyzing biological and social network data. Here we extend the Indian Buffet Process (IBP), a nonparametric Bayesian model, to integrate noisy interaction scores with properties of individual entities for inferring interaction networks and clustering nodes within these networks. We present an application of this method to study how microR-NAs regulate mRNAs in cells. Analysis of synthetic and real data indicates that the method improves upon prior methods, correctly recovers interactions and clusters, and provides accurate biological predictions.

Micro RNAs (miRNA) are a type of non-coding RNA, which are involved in gene regulation and can be associated with diseases such as cancer, cardiovascular and neurological diseases. As such, identifying the entire genome of miRNA can be of great relevance. Since experimental methods for novel precursor miRNA (pre-miRNA) detection are complex and expensive, computational detection using ML could be useful. Existing ML methods are often complex black boxes, which do not create an interpretable structural description of pre-miRNA. In this paper, we propose a novel framework, which makes use of generative modeling through Variational Auto-Encoders to uncover the generative factors of pre-miRNA. After training the VAE, the pre-miRNA description is developed using a decision tree on the lower dimensional latent space. Applying the framework to miRNA classification, we obtain a high reconstruction and classification performance, while also developing an accurate miRNA description.

The recent development of high-throughput sequencing creates a large collection of multi-omics data, which enables researchers to better investigate cancer molecular profiles and cancer taxonomy based on molecular subtypes. Integrating multi-omics data has been proven to be effective for building more precise classification models. Current multi-omics integrative models mainly use early fusion by concatenation or late fusion based on deep neural networks. Due to the nature of biological systems, graphs are a better representation of bio-medical data. Although few graph neural network (GNN) based multi-omics integrative methods have been proposed, they suffer from three common disadvantages. One is most of them use only one type of connection, either inter-omics or intra-omic connection; second, they only consider one kind of GNN layer, either graph convolution network (GCN) or graph attention network (GAT); and third, most of these methods lack testing on a more complex cancer classification task. We propose a novel end-to-end multi-omics GNN framework for accurate and robust cancer subtype classification. The proposed model utilizes multi-omics data in the form of heterogeneous multi-layer graphs that combines both inter-omics and intra-omic connections from established biological knowledge. The proposed model incorporates learned graph features and global genome features for accurate classification. We test the proposed model on TCGA Pan-cancer dataset and TCGA breast cancer dataset for molecular subtype and cancer subtype classification, respectively. The proposed model outperforms four current state-of-the-art baseline models in multiple evaluation metrics. The comparative analysis of GAT-based models and GCN-based models reveals that GAT-based models are preferred for smaller graphs with less information and GCN-based models are preferred for larger graphs with extra information.

MicroRNAs (miRNAs) play pivotal roles in gene expression regulation by binding to target sites of messenger RNAs (mRNAs). While identifying functional targets of miRNAs is of utmost importance, their prediction remains a great challenge. Previous computational algorithms have major limitations. They use conservative candidate target site (CTS) selection criteria mainly focusing on canonical site types, rely on laborious and time-consuming manual feature extraction, and do not fully capitalize on the information underlying miRNA-CTS interactions. In this paper, we introduce TargetNet, a novel deep learning-based algorithm for functional miRNA target prediction. To address the limitations of previous approaches, TargetNet has three key components: (1) relaxed CTS selection criteria accommodating irregularities in the seed region, (2) a novel miRNA-CTS sequence encoding scheme incorporating extended seed region alignments, and (3) a deep residual network-based prediction model. The proposed model was trained with miRNA-CTS pair datasets and evaluated with miRNA-mRNA pair datasets. TargetNet advances the previous state-of-the-art algorithms used in functional miRNA target classification. Furthermore, it demonstrates great potential for distinguishing high-functional miRNA targets.